bromodeoxyuridine has been researched along with kyn 54 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, A; Makita, H; Mori, H; Ohnishi, M; Satoh, K; Tamai, Y; Tanaka, T; Torihara, M; Yamahara, J | 1 |
| Kawamori, T; Mori, H; Okamoto, K; Suzui, M; Tamai, Y; Tanaka, T; Torihara, M; Yamahara, J | 1 |
2 other study(ies) available for bromodeoxyuridine and kyn 54
| Article | Year |
|---|---|
Inhibition of 4-nitroquinoline-1-oxide-induced rat oral carcinogenesis by dietary exposure of a new retinoidal butenolide, KYN-54, during the initiation and post-initiation phases.
Topics: 4-Butyrolactone; 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Biogenic Polyamines; Bromodeoxyuridine; Carcinogens; Cell Division; Male; Mouth Neoplasms; Nuclear Proteins; Nucleolus Organizer Region; Precancerous Conditions; Rats; Rats, Inbred F344; Retinoids; Silver Staining | 1995 |
Chemoprevention of azoxymethane-induced intestinal carcinogenesis by a novel synthesized retinoidal butenolide, 5-hydroxy-4-(2-phenyl-(E)-ethenyl)-2(5H)-furanone, in rats.
Topics: 4-Butyrolactone; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Azoxymethane; Biomarkers, Tumor; Bromodeoxyuridine; Colon; Dose-Response Relationship, Drug; Epithelium; Intestinal Neoplasms; Male; Ornithine Decarboxylase; Precancerous Conditions; Rats; Rats, Inbred F344; Retinoids | 1995 |